Price (90d)
$64.12Signal Score (90d)
50Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $48.20B | $7.05B | $3.46 |
| 2024 | $48.30B | $-8.95B | $-4.41 |
| 2023 | $45.01B | $8.03B | $3.88 |
| 2022 | $46.16B | $6.33B | $2.97 |
| 2021 | $46.38B | $6.99B | $3.15 |
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $1.68 per share
Typical surprise +13.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$2.04 vs $1.60beat
- Thu, Apr 30$1.58 vs $1.42beat
- Thu, Feb 5$1.26 vs $1.23beat
- Thu, Oct 30$1.63 vs $1.52beat
- Thu, Jul 31$1.46 vs $1.09beat
- Thu, Apr 24$1.80 vs $1.49beat
Estimates and results for BMY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BMY's reported EPS growth of 2.4% a year over 4 years.
- EPS in 5 years
- $3.89
- Implied price
- $62.26
- Return from $63.83
- -0.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $30.95 — -51.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -7.6% | -15.2% | -12.6% | -10.2% | -8.1% | -6.1% |
| -2.6% | -10.6% | -7.8% | -5.4% | -3.1% | -1.0% |
| 2.4% | -6.1% | -3.1% | -0.5% | 1.9% | 4.0% |
| 7.4% | -1.5% | 1.6% | 4.4% | 6.8% | 9.1% |
| 12.4% | 3.1% | 6.3% | 9.2% | 11.8% | 14.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (10)
- Newszacks.com·23h ago·Neutral
Can BMY's First CELMoD Approval Support Its Growth Strategy? Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.
View source ↗ - Newsbusinesswire.com·1d ago·Neutral
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS.
View source ↗ - Newsreuters.com·1d ago·Neutral
US FDA approves Bristol Myers' blood cancer treatment The U.S. FDA on Thursday approved Bristol Myers Squibb's combination treatment for patients with a rare form of blood cancer whose illness had relapsed or not responded to other treatments, the health regulator said.
View source ↗ - Newsreuters.com·2d ago·Negative
Lawsuit against Bristol Myers over delayed cancer drug is revived A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs, including the cancer treatment Breyanzi.
View source ↗ - Newszacks.com·3d ago·Negative
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines? Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.
View source ↗ - News (Marketaux)insidermonkey.com·4d ago·Positive
Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY Bristol-Myers Squi[+255 characters]
View source ↗ - Newszacks.com·5d ago·Positive
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock? Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.
View source ↗ - Newsreuters.com·5d ago·Negative
Bristol Myers to build $2.3 billion manufacturing site in Houston Drugmaker Bristol Myers Squibb on Monday said it will spend about $2.3 billion to build a new manufacturing facility in Houston, Texas, part of a previously announced $40 billion commitment to invest in the United States.
View source ↗ - Newsbusinesswire.com·5d ago·Neutral
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas.
View source ↗ - News (Alpha Vantage)Bloomberg·12d ago·Positive
Watch Tyson Falls on 3Q Results; Bristol-Myers Squibb Surges on Potential Acquisition | Stock Movers Bristol-Myers Squibb (SQB) shares surged due to news of a potential acquisition by AstraZeneca (AZN), whose shares dropped. Tyson (TSN) shares fell after reporting a 3Q sales shortfall, particularly in beef, and cutting full-year profit forecasts. SpaceX (SPCX) investors are preparing for the company's first earnings report as a public entity.
View source ↗